Sanofi
SNY Healthcare Drug Manufacturers General
Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024. In the quarter to June 2026, revenue grew 17.4%, EPS fell 90.8%, free cash flow fell 45.1% and total debt rose 8.23%, each against the same quarter a year earlier. Dividend growth for three consecutive years.
Follow SNY
Sanofi (SNY) Altman Z-score
Sanofi's Altman Z-score for fiscal 2025 is 2.50, in the grey zone (1.81–2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 2.50 | (0.08) |
| FY2024 | 2.58 | (0.15) |
| FY2023 | 2.73 | (0.06) |
| FY2022 | 2.79 | 0.17 |
| FY2021 | 2.62 | (0.25) |
| FY2020 | 2.87 | 0.36 |
| FY2019 | 2.51 | 0.25 |
| FY2018 | 2.25 | (0.62) |
| FY2017 | 2.87 | 0.35 |
| FY2016 | 2.52 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.02 | — | 0.02 | |
| Retained earnings / total assets | 0.53 | — | 0.74 | |
| EBIT / total assets | 0.07 | — | 0.23 | |
| Market value of equity / total liabilities | 1.90 | — | 1.14 | |
| Sales / total assets | 0.37 | — | 0.37 | |
| Altman Z-score | Grey zone | 2.50 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 3.68 | ||
Z and Z″ put Sanofi in different zones: grey zone by Z, safe zone by Z″.
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| AZN AstraZeneca PLC compare | 6.3× |
| NVO Novo Nordisk A/S compare | 4.3× |
| NVS Novartis AG compare | 4.1× |
| GILD Gilead Sciences, Inc. compare | 4.0× |
| SNY Sanofi | 2.5× |
| BMY Bristol Myers Squibb Company compare | 2.1× |
| GSK GSK PLC Sponsored ADR compare | 2.1× |
| PFE Pfizer Inc. compare | 2.0× |
| AMGN Amgen Inc. compare | 1.7× |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets